Luciano Santollani

Jan 3, 2024 | biorxiv.org | Luciano Santollani |Yiming Zhang |Laura Maiorino |Joseph R Palmeri

AbstractCytokine therapies are potent immunotherapy agents but exhibit severe dose-limiting toxicities. One strategy to overcome this involves engineering cytokines for intratumoral retention following local delivery. Here, we develop a localized cytokine therapy that elicits profound anti-tumor immunity by engineered targeting to the ubiquitous leukocyte receptor CD45.